Modifications of the catalytic and binding subunits of pertussis toxin by formaldehyde: Effects on toxicity and immunogenicity

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2329-2337

  Fowler, Sarah ^a   Xing, Dorothy K L ^a   Bolgiano, Barbara ^a   Yuen, Chun Ting ^a   Corbel, Michael J ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Formaldehyde; Pertussis toxin; Toxoids

Indexed keywords

FORMALDEHYDE; HISTAMINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PERTUSSIS TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELL ASSAY; CELL STRAIN; CHINESE HAMSTER; CONTROLLED STUDY; DRUG DETOXIFICATION; FEMALE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MODIFICATION; REDUCTION; SENSITIZATION; TOXICITY TESTING;

EID: 0038523754     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00104-X     Document Type: Article

References (43)

1. Pittman M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev. Infect. Dis. 1:1979;401-412.
2. Weiss A.A., Hewlett E.L., Myers G.A., Falkow S. Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis. J. Infect. Dis. 150:1984;219-222.
3. Munoz JJ. Biological activities of pertussigen (pertussis toxin). In: Sekura RD, Moss J, Vaughan M, editors. Pertussis toxin. London: Academic Press; 1985. p. 1-18.
4. Nencioni L., Volpini G., Peppoloni S., Bugnoli M., De Magistris M.T., Marsili I.et al. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect. Immun. 59:1991;625-630.
5. Petre J., Pizza M., Nencioni L., Podda A., De Magistris M.T., Rappuoli R. The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. Dev. Biol. Stand. 87:1996;125-134.
6. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 1:1984;122-126.
7. Gupta R.K., Saxena S.N., Sharma S.B., Ahuja S. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques. Dev. Biol. Stand. 73:1991;205-222.
8. Bolgiano B., Fowler S., Turner K., Sesardic D., Xing D.K.-L., Crane D.T.et al. Monitoring of protein vaccine components by CD, fluorescence spectroscopy and size exclusion chromatography. Dev. Biol. Stand. 103:2000;51-59.
9. Fowler S, Bolgiano B, Byron O, Xing DK-L, Corbel MJ. Pertussis toxin: effects of formaldehyde on structural properties. In: Proceedings for the Ninth European Workshop on Bacterial Protein Toxins. Int J Med Microbiol 2000;290:A63.
10. Nencioni L., Pizza M., Bugnoli M., De Magistris M.T., Di Tommaso A., Giovannoni F.et al. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect. Immun. 58:1990;1308-1315.
11. Mach H., Middaugh C.R., Lewis R.V. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Anal. Biochem. 200:1992;74-80.
12. Locht C., Keith J.M. Pertussis toxin gene: nucleotide sequence and genetic organization. Science. 232:1986;1258-1264.
13. Gillenius P., Jaatmaa E., Askelof P., Granstrom M., Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J. Biol. Stand. 13:1985;61-66.
14. Yuen C.-T., Canthaboo C., Menzies J.A., Cyr T., Whitehouse L.W., Jones C.et al. Detection of residual pertussis toxin in vaccines using a modified ribosylation assay. Vaccine. 21:2002;44-52.
15. Fowler S. Structural and immunological studies of pertussis toxins: effect of toxoiding. Ph.D. thesis, British Library, London, 2001.
16. Di Tommaso A., De Magistris M.T., Bugnoli M., Marsili I., Rappuoli R., Abrignani S. Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infect. Immun. 62:1994;1830-1834.
17. Ryan M., McCarthy L., Rappuoli R., Mahon B.P., Mills K.H. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int. Immunol. 10:1998;651-662.
18. Wilson A.D., Robinson A., Irons L., Stokes C.R. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine. 11:1993;113-118.
19. Shive C.L., Hofstetter H., Arredondo L., Shaw C., Forsthuber T.G. The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells. Eur. J. Immunol. 30:2000;2422-2431.
20. Xing D.K.-L., Canthaboo C., Corbel M.J. Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo. Vaccine. 18:2000;2110-2119.
21. Koh W.S., Yang K.H., Kaminski N.E. Cyclic AMP is an essential factor in immune responses. Biochem. Biophys. Res. Commun. 206:1995;703-709.
22. Bell J.D., Brunton L.L. Enhancement of adenylate cyclase activity in S49 lymphoma cells by phorbol esters. Withdrawal of GTP-dependent inhibition. J. Biol. Chem. 261:1986;12036-12041.
23. Bihoreau C., Heurtier A., Enjalbert A., Corvaia N., Bensussan A., Degos L.et al. Activation of the CD3/T-cell receptor (TcR) complex or of protein kinase C potentiate adenylyl cyclase stimulation in a tumoral T-cell line: involvement of two distinct intracellular pathways. Eur. J. Immunol. 21:1991;2877-2882.
24. Kvanta A., Gerwins P., Jondal M., Fredholm B.B. Stimulation of T cells with OKT3 antibodies increases forskolin binding and cyclic AMP accumulation. Cell. Signal. 2:1990;461-470.
25. Lerner A., Jacobson B., Miller R.A. Cyclic AMP concentrations modulate both calcium flux and hydrolysis of phosphatidylinositol phosphates in mouse T lymphocytes. J. Immunol. 140:1988;936-940.
26. Anastassiou E.D., Paliogianni F., Balow J.P., Yamada H., Boumpas D.T. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J. Immunol. 148:1992;2845-2852.
27. Imboden J.B., Shoback D.M., Pattison G., Stobo J.D. Cholera toxin inhibits the T-cell antigen receptor-mediated increases in inositol trisphosphate and cytoplasmic free calcium. Proc. Natl. Acad. Sci. U.S.A. 83:1986;5673-5677.
28. Novak T.J., Rothenberg E.V. cAMP inhibits induction of interleukin-2 but not of interleukin-4 in T cells. Proc. Natl. Acad. Sci. U.S.A. 87:1990;9353-9357.
29. Kammer G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today. 9:1988;222-229.
30. Krause D.S., Deutsch C. Cyclic AMP directly inhibits IL-2 receptor expression in human T cells: expression of both p55 and p75 subunits is affected. J. Immunol. 146:1991;2285-2296.
31. Johnson K.W., Davis B.H., Smith K.A. cAMP antagonizes interleukin-2-promoted T-cell cycle progression at a discrete point in early G1. Proc. Natl. Acad. Sci. U.S.A. 85:1988;6072-6076.
32. Chakkalath H.R., Jung L.K. Augmentation of phorbol ester-induced T-cell proliferation by agents which raise intracellular cyclic adenosine monophosphate. Cell. Immunol. 145:1992;240-253.
33. Scholz W., Altman A. Synergistic induction of interleukin-2 receptor (TAC) expression on YT cells by interleukin-1 or tumor necrosis factor alpha in combination with cAMP inducing agents. Cell. Signal. 1:1989;367-375.
34. Quentin-Millet M.J., Arminjon F., Danve B., Cadoz M., Armand J. Acellular pertussis vaccines: evaluation of reversion in a nude mouse model. J. Biol. Stand. 16:1988;99-108.
35. Ausiello C.M., Urbani F., la Sala A., Lande R., Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65:1997;2168-2174.
36. Mills K.H., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:1998;594-602.
37. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L.et al. Distinct T-cell subtypes induced with whole-cell and acellular pertussis vaccines in children. Immunology. 93:1998;1-10.
38. Fowler S, Byron O, Jumel K, Xing DK-L, Corbel MJ, Bolgiano B. Novel configurations of high molecular weight species of the pertussis toxin vaccine component. Vaccine, in press.
39. Ausiello C.M., Fedele G., Urbani F., Lande R., Di Carlo B., Cassone A. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J. Infect. Dis. 186:2002;351-360.
40. Tonon S., Goriely S., Aksoy E., Pradier O., Del Guidice G., Trannoy E.et al. Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. Eur. J. Immunol. 32:2002;3118-3125.
41. Bagley K., Abdelwahab S., Tuskan R., Fouts T., Lewis G. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J. Leukoc. Biol. 72:2002;962-969.
42. Ballou L., Laulederkind S., Rosloniec E., Raghow R. Ceramide signaling and the immune response. Biochim. Biophys. Acta. 1301:1996;273-287.
43. Ryan E., McNeela E., Pizza M., Rappuoli R., Neill L., Mills K. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: pro- and anti-inflammatory effects of the non-toxic AB complex and the enzyme activity. J. Immun. 165:2000;5750-5759.